EndoCompass Project: Research Roadmap for Pituitary and Neuroendocrine Tumor Endocrinology

Endocrine science remains underrepresented in European Union research programs despite the fundamental role of hormone health in human wellbeing. Analysis of the CORDIS database reveals a persistent gap between the societal impact of endocrine disorders and their research prioritization. At national funding level, endocrine societies report limited or little attention of national research funding toward endocrinology. The EndoCompass project - a joint initiative between the European Society of Endocrinology and the European Society of Paediatric Endocrinology, aimed to identify and promote strategic research priorities in endocrine science to address critical hormone-related health challenges.

Research priorities were established through comprehensive analysis of the EU CORDIS database covering the Horizon 2020 framework period (2014-2020). Expert consultation in pituitary and neuroendocrine tumor endocrinology was conducted to identify key research priorities, followed by broader stakeholder engagement including society members and patient advocacy groups.

Research priorities encompass congenital and acquired disorders, tumor development and progression, and neuroendocrine neoplasms. Key areas include genetic/epigenetic factors, tumor microenvironment, personalized treatment approaches, developing preclinical models, and implementing artificial intelligence. Special emphasis is placed on aggressive tumors, hypothalamic syndromes, and establishing pan-European biobanks and databases.

This component of the EndoCompass project provides an evidence-based roadmap for strategic research investment. This framework identifies crucial investigation areas into pituitary-neuroendocrine disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of these disorders on individuals and society. The findings support the broader EndoCompass objective of aligning research funding with areas of highest potential impact in endocrine health.